Alliances in Therapeutic Innovation: Opportunities for Early Stage Drug Discovery and Development Collaborations

Request Number N335118
Need details

Pfizer Worldwide R&D (WRD) organisation is interested in establishing early stage alliances to develop novel therapeutics, expand the understanding of disease biology and identify biomarkers for diseases/indications of significant unmet medical need globally and also with a higher and growing prevalence in Asia.


Such diseases include, but are not limited to, Type 2 diabetes (particularly young and low BMI diabetes) and related complications, hepatocellular carcinoma (HCC), gastric cancer and COPD.


Pfizer seeks to provide funding to a limited number of Asia’s leading academic and biotechnology groups to create new partnerships that address this need.  Funding from US$50,000 to US$1.0M may be provided to support research collaborations that can help transition these opportunities from the academic environment into new start-up companies.


Key Success Criteria:

This challenge is open to:

    1. Asia Pacific academic & biotechnology researchers seeking to transition their discoveries into start-up companies within or outside of the region
    2. Academic & biotechnology researchers seeking to transition their discoveries into start-up companies in the Asia Pacific region


Proposals will be assessed upon:

    1. Scientific merit and novelty
    2. Ability to meet measurable annual milestones
    3. Track record of the Principle Investigators and key team members



has established a number of novel approaches to work with partners to develop new medicines. Moving beyond traditional collaborations and licensing deals, Pfizer is actively seeking to support early stage discovery research programs. Pfizer currently supports numerous collaborative partnerships with some of the world's leading academic researchers. We now seek new opportunities to collaborate with early stage programs that are initiated from within Asia Pacific universities, research institutes and biotechnology companies.


We are committed to exploratory research and have empowered our Asia External R&D Innovation team to identify and invest in opportunities that align with our core research interests and to support early-stage technologies so they might transition from a pure academic environment into new start-up companies.


Possible Approaches:

Pfizer Worldwide R&D strategically focuses on developing differentiated therapeutics for patients globally in the areas of Cardiovascular & Metabolic Disorders, Inflammation & Immunology, Neuroscience & Pain,  Oncology, Rare Diseases & Vaccines (for details, see We are particularly interested in supporting programs that are developing novel biomarkers, diagnostics, targets and therapeutics in the above mentioned disease areas and that leverage Asia advantages (e.g. prevalent indications or government incentives etc).


Approaches Not of Interest:

    1. Proposals for block funding collaborations that do not have specific and defined milestones that can be reasonably met within a two year time period
    2. Proposals that fall outside of our key therapeutic areas of interest (for details, see
    3. Approaches targeting opthamology and anti-infective
    4. Approaches for diseases of low prevalence in Asia


Preferred Collaboration Type:

Pfizer’s WRD External R&D Innovation Division has allocated fund to provide up to $1.0M to establish and progress early stage research collaborations.  For appropriate opportunities, Pfizer may also provide access to many of our key capabilities and drug discovery and development resources.  We are seeking opportunities to establish truly collaborative relationships that bring a high level of interaction between our R&D groups and appropriate partner organizations.


How to Respond:

We are looking for a completed Response Template, which may contain a concise abstract/executive summary. The proposal should briefly describe the technical approach and provide information on technology performance, background and description of the responding team and their related experience. To Respond, please use the red Respond Now button located to the right. Please note that only non-confidential information can be accepted.


By submitting a response you represent that the response does not contain and will not be deemed to contain any confidential information of any kind whatsoever. All Personal Information disclosed to Pfizer within a response will be utilized in accord with principles and polices as described at By submitting a response, you also acknowledge and confirm that you have consulted with your Technology Transfer Office, Business Development Office or any other required group and that you have their approval to submit the response. By submitting a response, you acknowledge that the Need's sponsoring organization, in its sole discretion, may select or reject a response or any portion thereof.


Your NineSights community profile should contain all required information in order to provide us with appropriate contact information for your responses. For questions about NineSights privacy and security, please feel free to post in our forums.

Migrated from previous NineSights Community Site
Key Success Criteria
Migrated from previous NineSights Community Site
Preferred Collaboration types
  • To Be Negotiated
Point of Contact
Jonathan Tzeng
Area of Interest
  • Chemical Manufacturing
  • Family & Consumer Products & Services
  • Financial Services
  • Medical Products & Services
  • Packaging
  • Professional Services
  • Other
Due Date
April 11, 2014
Award Amount
This page does not have file attachments.
This page does not have file attachments.